中文

Agios (AGIO)

Biotech

Close on Nov 10, 2026 (from our latest Long View update): $31.76

Market value
$1.9Bat the Nov 10 close
Revenue growth
+214%12 months to Sep 30, 2026 (10-Q)
FCF margin
−239%12 months to Sep 30, 2026 (10-Q)
Net cash
$907Mat Sep 30, 2026
Worst fall since listing
−87.4%Jan 14, 2015 to Jun 14, 2022; not back to that high (−78.7% now)

About the company

Latest

The Long View

Agios sold its cancer business in 2021 to focus on rare blood diseases, then used the cash for a large buyback and its own launches.

▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash

Updated Nov 11, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for Agios, FY2011–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $22M in FY2011 to $54M in FY2025. Free cash flow was positive in 1 of the 15 years shown; FY2025: −$377M. Each year's figures are in the table below. −$600M−$400M−$200M$0$200M ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $22M in FY2011 to $54M in FY2025.

Free cash flow was positive in 1 of the 15 years shown; FY2025: −$377M.

Margins

Margins are not charted: in FY2025 the operating loss (−$472M) was larger than revenue ($54M). The table has each year's figures.

Diluted share count

The diluted share count fell 16% from FY2020 to FY2025, to 58M. Each year's figures are in the table below. 50M55M60M65M70M ’19’20’21’22’23’24’25

The diluted share count fell 16% from FY2020 to FY2025, to 58M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$54M—−874%−$413M−$373M$4M−$377M
FY2024$36M—−1166%$674M−$390M$2M−$392M
FY2023$27M—−1460%−$352M−$296M$1.0M−$297M
FY2022$14M—−2732%−$232M−$309M$5M−$314M
FY2021$0——$1.6B−$407M$6M−$413M
FY2020$0——−$327M−$291M$14M−$305M
FY2019$118M—−268%−$411M−$371M$12M−$383M
FY2018$94M—−384%−$346M−$304M$7M−$311M
FY2017$43M—−746%−$315M−$285M$5M−$290M
FY2016$70M—−288%−$198M$39M$10M$29M
FY2015$59M—−201%−$118M−$77M$20M−$97M
FY2014$65M—−83%−$54M−$59M$2M−$62M
FY2013$26M—−152%−$39M−$56M$1M−$58M
FY2012$25M—−92%−$20M−$50M$1M−$51M
FY2011$22M—−76%−$24M−$15M$2M−$17M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202558M$1.2B—$53M——
FY202458M$1.5B—$43M——
FY202356M$806M—$45M—$0
FY202255M$1.1B—$49M—$0
FY202160M$1.3B$0.6M$54M—$802M
FY202069M$671M$0.6M$62M—$0
FY201960M$718M$0.9M$58M—$0
FY2018—$805M—$73M——
FY2017—$103M—$48M——
FY2016—$541M—$42M——
FY2015—$317M—$32M——
FY2014—$342M—$12M——
FY2013—$167M—$3M——
FY2012—$128M—$0.7M——
FY2011—$118M—$0.4M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 5, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearAGIOS&P 500
2019+3.6%+31.5%
2020−9.3%+18.4%
2021−24.1%+28.7%
2022−14.6%−18.1%
2023−20.7%+26.3%
2024+47.5%+25.0%
2025−17.2%+17.9%
2026 to date+5.7%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Agios

How does Agios make money?
Agios earns product revenue from mitapivat, an oral pyruvate kinase activator used to treat inherited anemias. In the US, it markets the drug as PYRUKYND for PK deficiency and AQVESME for thalassemia. Revenue was $54.0M in 2025. More in the Long View →
What could drive Agios's growth?
Agios's strategy combines expanding mitapivat into additional blood diseases, especially sickle cell disease, with developing other medicines. Its pipeline includes AG-236 for polycythemia vera, cevidoplenib for immune thrombocytopenia and AG-181 for phenylketonuria; these are investigational treatments. More in the Long View →
Why does Agios's thalassemia drug need a safety program?
In the US, AQVESME is restricted through a REMS because of liver-injury risk. The program requires regular liver testing, patient enrollment, and certified prescribers and pharmacies; PYRUKYND for PK deficiency does not require a REMS. More in the Long View →
What are the main risks to Agios's business?
Agios depends on mitapivat for product revenue. Its operations have consumed more cash than they generate, making funding its development and commercialization spending a central business risk. More in the Long View →
How has Agios funded itself?
Asset sales have been an important part of Agios's funding strategy: it sold its oncology business in 2021 and specified vorasidenib royalty rights in 2024. It also spent $802.5M on share repurchases in 2021. More in the Long View →
What's coming up for Agios's pipeline in the next 12 months?
Agios says the FDA's PDUFA goal date for mitapivat in sickle cell disease is February 1, 2027. By year-end 2026, Agios plans to start a Phase 2/3 program of AG-236 in polycythemia vera and expects Phase 1b proof-of-mechanism data for AG-181 in patients with phenylketonuria. As of Nov 5, 2026 More in the Long View →